CDH11

(redirected from CAD11)

CDH11

A gene on chromosome 16q21 that encodes a calcium-dependent cell–cell adhesion glycoprotein (cadherin), which is involved in regulating cell–cell adhesions, mobility and proliferation of epithelial cells. CDH11 is a so-called type-II (atypical) cadherin—which lacks a HAV cell adhesion recognition sequence specific to type-I cadherins—and is expressed in osteoblastic cell lines. It is upregulated during differentiation, suggesting a role during in bone development and maintenance.

Molecular pathology
Defects in CDH11 commonly occur in aneurysmal bone cysts and consist of a translocation t(16;17)(q22;p13) with USP6.
Mentioned in ?
References in periodicals archive ?
Additionally, the company disclosed the redemption price consists of the sum of the present values of the remaining scheduled payments of principal and interest on the notes (exclusive of interest accrued to the redemption date) of CAD504.11m (based on a benchmark treasury rate of 1.508% plus 45 basis points), plus CAD11.5m in accrued and unpaid interest to the redemption date for the notes, in accordance with the terms of the indenture governing the notes.
is the investment adviser to the First Investors family of funds, which had nearly CAD11 billion in total assets under management as of December 31, 2015.
* Software sales : CAD11.7bn in 2013 to CAD12.1bn in 2014, an increase of 3.7%.
18 October 2013 - UK scientific digital camera maker Andor Technology plc (LON:AND) said today it had acquired Spectral Applied Research Inc, a Canadian manufacturer of optical systems for cell biology research, for CAD11.3m (USD11m/EUR8m) in cash.
According to the contract, Petrominerales shareholders will receive CAD11 cash for each Petrominerales common share held, for a total value of around CAD935m in cash and one common share of a newly formed exploration and production company and the assumption of net debt estimated at CAD640m, including convertible bonds.
The amount allocated for Vioxx users in Canada will be between CAD11.3m and CAD26.4m depending on the final number of eligible claims.
Total revenue was CAD10.77bn for the second quarter of 2011, compared to CAD11.7bn for the same period a year ago.
The company is reporting net earnings of CAD422,000 or CAD0.02 per share on revenues of CAD13.8m for the quarter ended May 27, 2011, compared to a net loss of CAD364,000 or CAD0.02 per share on revenues of CAD11.6m for the quarter ended May 28, 2010.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) were up 21.5% to CAD14.2m, or 16.5% of sales, compared with CAD11.7m, or 15.2% of sales, last year.
Canadian banks had write-downs of CAD11.6bn in the previous 12 months.
* Software sales: CAD10.8bn in 2013 to CAD11.2bn in 2014, an increase of 3.7%.
As a result, the company is entitled to receive a termination fee of CAD11.6m (USD11.5m/EUR8.5m) from Orko Silver.